WallStSmart

Merck & Company Inc (MRK)vsNeuronetics Inc (STIM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 43272% more annual revenue ($65.77B vs $151.64M). MRK leads profitability with a 13.6% profit margin vs -24.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

STIM

Avoid

29

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 4/9Altman Z: -3.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
STIMUndervalued (+82.3%)

Margin of Safety

+82.3%

Fair Value

$10.20

Current Price

$1.39

$8.81 discount

UndervaluedFair: $10.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

STIM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

STIM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$89.77M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.823/10

Elevated debt levels

Return on EquityProfitability
-131.6%2/10

ROE of -131.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : STIM

STIM has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : STIM

The primary concerns for STIM are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.82 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while STIM is a turnaround play — different risk/reward profiles.

STIM carries more volatility with a beta of 1.04 — expect wider price swings.

STIM is growing revenue faster at 7.8% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). STIM offers better value entry with a 82.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Neuronetics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.

Want to dig deeper into these stocks?